Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.

IF 2.5 4区医学 Q2 DERMATOLOGY

Photodermatology, photoimmunology & photomedicine Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI:10.1111/phpp.12936

Ilit Mimouni, Julia Shulman, Awni Abu Unes, Lev Pavlovsky, Felix Pavlotsky

{"title":"Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.","authors":"Ilit Mimouni, Julia Shulman, Awni Abu Unes, Lev Pavlovsky, Felix Pavlotsky","doi":"10.1111/phpp.12936","DOIUrl":null,"url":null,"abstract":"Background: Narrowband ultraviolet B (NB-UVB) phototherapy is a popular and relatively contemporary treatment option. However, only a few studies to date have explored the potential risk of skin cancer following NB-UVB treatment.Objective: This study aimed to investigate the potential long-term risk of skin cancer in patients treated with NB-UVB.Methods: This cohort study included patients with psoriasis, vitiligo, and mycosis fungoides treated with NB-UVB at two university hospitals in Israel in 2000-2005. Patients were followed up for skin cancer for at least 10 years. Data were extracted from the hospital and community medical records.Results: A total of 767 patients were included in this study: 509 with psoriasis, 122 with vitiligo, and 136 with mycosis fungoides. The mean follow-up duration was 13 years. Among these patients, 4.43% developed skin cancer during the follow-up (3.93% had psoriasis, 2.46% had vitiligo, and 8.09% had mycosis fungoides). Old age and fair skin type were the only significant independent risk factors for skin cancer. There was no significant difference in the mean number of NB-UVB treatments among patients who developed skin cancer and those who did not (99.09 vs. 94.79, respectively).Conclusion: No association was observed between the number of NB-UVB treatments and carcinogenesis in any study group. Age is a significant risk factor, and older patients treated with NB-UVB should be followed up carefully.","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photodermatology, photoimmunology & photomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/phpp.12936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Narrowband ultraviolet B (NB-UVB) phototherapy is a popular and relatively contemporary treatment option. However, only a few studies to date have explored the potential risk of skin cancer following NB-UVB treatment.

Objective: This study aimed to investigate the potential long-term risk of skin cancer in patients treated with NB-UVB.

Methods: This cohort study included patients with psoriasis, vitiligo, and mycosis fungoides treated with NB-UVB at two university hospitals in Israel in 2000-2005. Patients were followed up for skin cancer for at least 10 years. Data were extracted from the hospital and community medical records.

Results: A total of 767 patients were included in this study: 509 with psoriasis, 122 with vitiligo, and 136 with mycosis fungoides. The mean follow-up duration was 13 years. Among these patients, 4.43% developed skin cancer during the follow-up (3.93% had psoriasis, 2.46% had vitiligo, and 8.09% had mycosis fungoides). Old age and fair skin type were the only significant independent risk factors for skin cancer. There was no significant difference in the mean number of NB-UVB treatments among patients who developed skin cancer and those who did not (99.09 vs. 94.79, respectively).

Conclusion: No association was observed between the number of NB-UVB treatments and carcinogenesis in any study group. Age is a significant risk factor, and older patients treated with NB-UVB should be followed up carefully.

查看原文本刊更多论文

窄带紫外线B光疗治疗银屑病、白癜风和蕈样真菌病患者皮肤癌的发生率

背景:窄带紫外线B (NB-UVB)光疗是一种流行且相对现代的治疗选择。然而，迄今为止只有少数研究探讨了NB-UVB治疗后皮肤癌的潜在风险。目的:本研究旨在探讨NB-UVB治疗患者患皮肤癌的潜在长期风险。方法:本队列研究纳入2000-2005年在以色列两所大学医院接受NB-UVB治疗的银屑病、白癜风和蕈样真菌病患者。对皮肤癌患者进行了至少10年的随访。数据从医院和社区医疗记录中提取。结果:本研究共纳入767例患者:509例银屑病，122例白癜风，136例蕈样真菌病。平均随访时间为13年。其中4.43%的患者在随访期间发生皮肤癌(其中银屑病3.93%，白癜风2.46%，蕈样真菌病8.09%)。年龄和白皙皮肤类型是皮肤癌的唯一显著独立危险因素。发生皮肤癌的患者和未发生皮肤癌的患者接受NB-UVB治疗的平均次数没有显著差异(分别为99.09比94.79)。结论:在任何研究组中，NB-UVB治疗次数与肿瘤发生均无相关性。年龄是重要的危险因素，使用NB-UVB治疗的老年患者应仔细随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Photodermatology, photoimmunology & photomedicine 医学-皮肤病学

CiteScore

4.40

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： The journal is a forum for new information about the direct and distant effects of electromagnetic radiation (ultraviolet, visible and infrared) mediated through skin. The divisions of the editorial board reflect areas of specific interest: aging, carcinogenesis, immunology, instrumentation and optics, lasers, photodynamic therapy, photosensitivity, pigmentation and therapy. Photodermatology, Photoimmunology & Photomedicine includes original articles, reviews, communications and editorials. Original articles may include the investigation of experimental or pathological processes in humans or animals in vivo or the investigation of radiation effects in cells or tissues in vitro. Methodology need have no limitation; rather, it should be appropriate to the question addressed.